Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results

Urology

Volumn 54, Issue 5, 1999, Pages 884-890

  Jhaveri, Faiyaaz M ^a   Zippe, Craig D ^a   Klein, Eric A ^a   Kupelian, Patrick A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

AGED; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 0032702052     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00252-6     Document Type: Article

References (36)

1. Oesterling J.E. Prostate specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate . J Urol. 145:1991;907-923.
2. Lange P.H., Ercole C.J., Lightner D.J., et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 141:1989;873-879.
3. Lightner D.J., Lange P.H., Reddy P.K., et al. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 144:1990;927-933.
4. Stamey T.A., Kabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II radical prostatectomy treated patients . J Urol. 141:1989;1076-1083.
5. Stein A., deKernion J.B., Smith R.B., et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 147:1992;942-946.
6. Partin A.W., Pound C.R., Clemens J.Q., et al. Serum PSA after anatomic radical prostatectomy the Johns Hopkins experience after 10 years . Urol Clin North Am. 20:1993;713-725.
7. Oefelein M.G., Smith N., Carter M., et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 154:1995;2128-2131.
8. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
9. Dillioglugil O., Leibman B.D., Kattan M.W., et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 50:1997;93-99.
10. Zincke H., Oesterling J.E., Blute M.L., et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 152:1994;1850-1857.
11. Kupelian P., Katcher J., Levin H., et al. Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 48:1996;249-260.
12. Catalona W.J., Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer intermediate-term results . J Urol. 160:1998;2428-2434.
13. Frazier H.A., Robertson J.E., Humphrey P.A., et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol. 149:1993;516-518.
14. Urological tumors prostate . Sobin L.H., Wittekind C. TNM Classification of Malignant Tumours. 1997;170-173 John Wiley & Sons, New York.
15. Harris E., Albert A. Survivorship Analysis for Clinical Studies. 1991;Marcel Dekker, New York.
16. Morgan W.R., Bergstralh E.J., Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology. 41:1993;113-120.
17. Paulson D.F. Impact of radical prostatectomy in the management of clinically localized disease. J Urol. 152:1994;1826-1830.
18. Stein A., deKernion J.B., Dorey F. Prostatic specific antigen related to clinical status 1 to 14 after radical prostatectomy. Br J Urol. 67:1991;626-631.
19. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical prostatectomy clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen . J Urol. 158:1997;1441-1445.
20. Ohori M., Goad J.R., Wheeler T.M., et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 154:1995;2128-2131.
21. Trapasso J.G., deKernion J.B., Smith R.B., et al. The incidence and significance of detectable levels of serum PSA after radical prostatectomy. J Urol. 152:1994;1821-1825.
22. Oefelein M.G., Grayhack J.T., McVay K.T. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate. Cancer. 76:1995;2535-2542.
23. Gerber G.S., Thisted R.A., Scardino P.T., et al. Results of radical prostatectomy in men with clinically localized prostate cancer multi-institutional pooled analysis . JAMA. 276:1996;615-619.
24. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 330:1994;242-248.
25. Albertsen P.C., Hanley J.A., Gleason D.F., et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 280:1998;975-980.
26. Lu-Yao G.L., Yao S. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 349:1997;906-910.
27. Partin A.W., Lee B.R., CarMicheal M., et al. Radical prostatectomy for high grade disease a reevaluation 1994 . J Urol. 151:1994;1583-1586.
28. Oefelein M.G., Smith N.D., Grayhack J.T., et al. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol. 158:1997;1460-1465.
29. Epstein J.I. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am. 23:1996;651-663.
30. Ohori M., Wheeler T.M., Kattan M.W., et al. Prognostic significance of positive margins in radical prostatectomy specimens. J Urol. 154:1995;1818-1824.
31. Ohori M., Abbas F., Wheeler T.M., et al. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 161:1999;500-504.
32. Rogers R., Grossfield G.D., Roach M., et al. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol. 160:1998;1748-1753.
33. Jhaveri F.M., Klein E.A., Kupelian P.A., et al. Declining rates of extracapsular extension in radical prostatectomy evidence for continued stage migration . J Clin Oncol. 17:1999;3245-3250.
34. Rietbergen J.B., Hoedemaeker R.F., Boeken Kruger A.E., et al. The changing pattern of prostate cancer at the time of diagnosis characteristics of screen detected prostate cancer in a population based screening study . J Urol. 161:1999;1192-1198.
35. Foster L.S., Jajodia P., Fournier G., et al. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostate fossa recurrence following radical prostatectomy. J Urol. 149:1993;1024-1028.
36. Cher M.L., Bianco F.J., Lam J.S., et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 160:1998;1387-1391.